BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.81 USD
-0.43 (-34.68%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.70%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCTX 0.81 -0.43(-34.68%)
Will BCTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCTX
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock
BCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCTX
BriaCell dips despite promising mid-stage data for breast cancer therapy
BriaCell Achieves Breakthrough in Breast Cancer Treatment
BriaCell reports anti-tumor response in patient treated in Phase 2 study
BriaCell Therapeutics Launches $5 Million Offering
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients